Multiplex Real-Time Reverse Transcription PCR for Influenza A Virus, Influenza B Virus, and Severe Acute Respiratory Syndrome Coronavirus 2

作者：Bo Shu, Marie K. Kirby, William G. Davis, Christine Warnes, Jimma Liddell, Ji Liu, Kai-Hui Wu, Norman Hassell, Alvaro J. Benitez, Malania M. Wilson, Matthew W. Keller, Benjamin L. Rambo‐Martin, Yamundow Camara, Jörn Winter, Rebecca J Garten Kondor, Bin Zhou, Stacey E. Spies, Laura Ellen Rose, Jonas M. Winchell, Brandi M. Limbago, David E. Wentworth, John Barnes · 发表于：Emerging infectious diseases · 年份：2021 · DOI：10.3201/eid2707.210462 · 被引用次数：120 · 研究领域：Influenza Virus Research Studies、Respiratory viral infections research、SARS-CoV-2 detection and testing

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019, and the outbreak rapidly evolved into the current coronavirus disease pandemic.SARS-CoV-2 is a respiratory virus that causes symptoms similar to those caused by infl uenza A and B viruses.On July 2, 2020, the US Food and Drug Administration granted emergency use authorization for in vitro diagnostic use of the Infl uenza SARS-CoV-2 Multiplex Assay.This assay detects infl uenza A virus at 10 2.0 , infl uenza B virus at 10 2.2 , and SARS-CoV-2 at 10 0.3 50% tissue culture or egg infectious dose, or as few as 5 RNA copies/reaction.The simultaneous detection and diff erentiation of these 3 major pathogens increases overall testing capacity, conserves resources, identifi es co-infections, and enables effi cient surveillance of infl uenza viruses and SARS-CoV-2.